Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Candesartan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 known ✓ | P30556 | 2/20 | 0.73 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.73 |
| ▸ | EGFR | P00533 | 1/20 | 0.73 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.73 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.73 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.73 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.73 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.73 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.73 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.73 |
| ▸ | HTR2C | P28335 | 1/20 | 0.73 |
| ▸ | PPARG | P37231 | 1/20 | 0.73 |
| ▸ | HTR2B | P41595 | 1/20 | 0.73 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.73 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.73 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Candesartan SCHEMBL3938 | 1.00 | AGTR1 (0.73) | AGTR1ABCB11EGFRERBB2CYP3A4 | |
| Candesartan SCHEMBL29682351 | 1.00 | AGTR1 (0.73) | AGTR1ABCB11EGFRERBB2CYP3A4 | |
| Candesartan SCHEMBL19357208 | 1.00 | AGTR1 (0.73) | AGTR1ABCB11EGFRERBB2CYP3A4 | |
| Candesartan SCHEMBL16237819 | 0.99 | AGTR1 (0.72) | AGTR1ABCB11EGFRERBB2CYP3A4 | |
| Candesartan SCHEMBL7292788 | 0.99 | AGTR1 (0.72) | AGTR1ABCB11EGFRERBB2CYP3A4 | |
| Candesartan SCHEMBL27825805 | 0.99 | AGTR1 (0.72) | AGTR1ABCB11EGFRERBB2CYP3A4 | |
| Candesartan SCHEMBL28786878 | 0.99 | AGTR1 (0.72) | AGTR1ABCB11EGFRERBB2CYP3A4 | |
| Candesartan SCHEMBL5507160 | 0.99 | AGTR1 (0.72) | AGTR1ABCB11EGFRERBB2CYP3A4 | |
| Candesartan SCHEMBL27825863 | 0.99 | AGTR1 (0.72) | AGTR1ABCB11EGFRERBB2CYP3A4 | |
| Candesartan SCHEMBL27825804 | 0.99 | AGTR1 (0.72) | AGTR1ABCB11EGFRERBB2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024167295-A1 | USE OF COMPOSITION CONTAINING CANDESARTAN OR AZILSARTAN | 가천대학교 산학협력단 | 2024-08-15 | — | — | WO | claimed |
| EP-4405339-A1 | PROCESS FOR PREPARING SARTANS | KRKA, d.d., Novo mesto (SI) | 2024-07-31 | — | — | EP | claimed |
| WO-2023046836-A1 | PROCESS FOR PREPARING SARTANS | KRKA, D.D., NOVO MESTO (SI) | 2023-03-30 | — | — | WO | claimed |
| CN-115282259-A | Oral spray preparation based on virus blocking agent and application thereof | 康码（上海）生物科技有限公司 | 2022-11-04 | — | — | CN | claimed |
| US-11433136-B2 | Polyacetal polymers, conjugates, particles and uses thereof | THE GENERAL HOSPITAL CORPORATION (US) | 2022-09-06 | — | — | US | claimed |
| US-12616807-B2 | Medical counter measures including dry powder formulations and associated methods | Belhaven BioPharma Inc. (US) | 2026-05-05 | — | — | US | disclosed |
| US-20260076897-A1 | DRY POWDER FORMULATIONS OF EPINEPHRINE AND ASSOCIATED METHODS | Belhaven BioPharma Inc. (US) | 2026-03-19 | — | — | US | disclosed |
| US-20260021042-A1 | DRY POWDER FORMULATIONS OF EPINEPHRINE AND ASSOCIATED METHODS | Belhaven BioPharma Inc. (US) | 2026-01-22 | — | — | US | disclosed |
| US-20260007594-A1 | DRY POWDER FORMULATIONS OF EPINEPHRINE AND ASSOCIATED METHODS | Belhaven BioPharma Inc. (US) | 2026-01-08 | — | — | US | disclosed |
| US-12414916-B2 | Dry powder formulations of epinephrine and associated methods | Belhaven BioPharma Inc. (US) | 2025-09-16 | — | — | US | disclosed |
| US-20250281653-A1 | METHODS FOR TREATING PROSTATE CANCER WITH RADIOPHARMACEUTICALS | ARTBIO INC (US) | 2025-09-11 | — | — | US | disclosed |
| US-20250179130-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | ON TARGET THERAPEUTICS LLC | 2025-06-05 | — | — | US | disclosed |
| WO-2022261453-A1 | DRY POWDER FORMULATIONS OF EPINEPHRINE AND ASSOCIATED METHODS | Belhaven BioPharma Inc. (US) | 2022-12-15 | — | — | WO | disclosed |
| US-20220395457-A1 | DRY POWDER FORMULATIONS OF EPINEPHRINE AND ASSOCIATED METHODS | Belhaven BioPharma Inc. (US) | 2022-12-15 | — | — | US | disclosed |
| US-11433136-B2 | Polyacetal polymers, conjugates, particles and uses thereof | THE GENERAL HOSPITAL CORPORATION (US) | 2022-09-06 | — | — | US | disclosed |
| US-11433063-B1 | Intranasal composition of pharmaceutical countermeasures for chemical warfare nerve agents and accidental exposure to organophosphate pesticides | BELHAVEN BIOPHARMA, INC. (US) | 2022-09-06 | — | — | US | disclosed |
| CN-114945372-A | Methods of treatment with myosin modulators | 迈奥卡迪亚公司 | 2022-08-26 | — | — | CN | disclosed |
| US-11389534-B2 | Methods of treating a subject for a condition | PALO ALTO INVESTORS (US) | 2022-07-19 | — | — | US | disclosed |
| US-20220135633-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | ON TARGET THERAPEUTICS LLC | 2022-05-05 | — | — | US | disclosed |
| CN-114173782-A | Treatment of cardiac contractile dysfunction and heart failure with reduced ejection fraction using the compound (R) -4- (1- ((3- (difluoromethyl) -1-methyl-1H-pyrazol-4-yl) sulfonyl) -1-fluoroethyl) -N- (isoxazol-3-yl) piperidine-1-carboxamide | 迈奥卡迪亚公司 | 2022-03-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135633-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | LDLR, HDLBP, LIPG | AGTR1 1339/4885ABCB11 4014/4885EGFR 404/4885 |
| US-11433136-B2 | Polyacetal polymers, conjugates, particles and uses thereof | CD44, FUT6, MSN | AGTR1 2514/4885ABCB11 581/4885EGFR 1672/4885 |
| US-20260007594-A1 | DRY POWDER FORMULATIONS OF EPINEPHRINE AND ASSOCIATED METHODS | ADRA1D, ADRB2, ADRB3 | AGTR1 74/4885ABCB11 1052/4885EGFR 2858/4885 |
| US-12616807-B2 | Medical counter measures including dry powder formulations and associated methods | ADRB2, ADRB3, MC5R | AGTR1 458/4885ABCB11 1198/4885EGFR 4084/4885 |
| US-20260021042-A1 | DRY POWDER FORMULATIONS OF EPINEPHRINE AND ASSOCIATED METHODS | ADRB2, ADRA1D, ADRA2C | AGTR1 189/4885ABCB11 545/4885EGFR 2468/4885 |
| US-20250281653-A1 | METHODS FOR TREATING PROSTATE CANCER WITH RADIOPHARMACEUTICALS | KLK3, FOLH1, ACP3 | AGTR1 2999/4885ABCB11 3523/4885EGFR 375/4885 |
| US-11433063-B1 | Intranasal composition of pharmaceutical countermeasures for chemical warfare nerve agents and accidental exposure to organophosphate pesticides | ACHE, CHRM3, CHRND | AGTR1 2191/4885ABCB11 1703/4885EGFR 2556/4885 |
| US-20260076897-A1 | DRY POWDER FORMULATIONS OF EPINEPHRINE AND ASSOCIATED METHODS | COMT, CMA1, ADRB3 | AGTR1 288/4885ABCB11 726/4885EGFR 4185/4885 |
| US-20250179130-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | LDLR, HDLBP, LIPG | AGTR1 1339/4885ABCB11 4014/4885EGFR 404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.